Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?

Rajshekhar Chakraborty, Navneet S. Majhail, Faiz Anwer

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?'. Together they form a unique fingerprint.